Junshi Biosciences Receives FDA Approval for PI3K-α Inhibitor RP903 in Breast Cancer Study
China’s Junshi Biosciences (HKG: 1877, SHA: 688180) announced that it has received approval from the...
InnoCare Pharma’s Guangzhou Plant Approved for Orelabrutinib Commercial Production
Beijing InnoCare Pharma (HKG: 9969) announced that as of June 30, its manufacturing plant in...
Hengrui Medicine’s Generic Tacrolimus Wins NMPA Approval for Transplant Rejection Prevention
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received market approval...
Medtronic Kanghui and Changzhou High-Tech Zone Partner on Science Park
Medtronic Kanghui and Changzhou National High-Tech Industrial Development Zone have agreed to collaborate on the...
NHC Releases Technical Guidelines for Drug Clinical Evaluation
The National Health Commission (NHC) has released the “Technical Guidelines for Comprehensive Clinical Evaluation of...
HitGen and Haichang Bio Partner to Develop Anti-Cancer RNAi Drugs
China-based HitGen Inc. (SHA: 688222) announced the establishment of a strategic partnership with compatriot firm...
Hainan Medical Products Administration Issues Guidelines for Imported Drug Management
The Hainan Medical Products Administration (HMPA) has released a set of guidelines that took effect...
Abbisko Therapeutics Doses First Patient in ABSK061 Phase I Study for Solid Tumors
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced the first patient dosing in a...
Ascletis Pharma Doses First Patient in ASC22 HIV Study with Chidamide
China-based Ascletis Pharma Inc. (HKG: 1672) announced that the first patient has been dosed in...
Fosun Pharmaceutical and ReNeuron Renew CTX Cell Therapy Deal for China
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has negotiated a new...
Eurofins DiscoverX Opens Shanghai Office to Expand Asia-Pacific Operations
California-based Eurofins DiscoverX Products LLC, a manufacturer of drug discovery solutions, announced the opening of...
Solasia Pharma Reduces China Operations, Transfers Drug Rights to Lee’s
Japan-based Solasia Pharma KK (TYO: 4597) announced that it will reduce its direct operations in...
NMPA Releases Plans to Support HK and Macau Drug, Device Production in Mainland Cities
The National Medical Products Administration (NMPA) has released two implementation plans aimed at supporting Hong...
Bio-Thera Solutions’ BAT8010 Receives NMPA Approval for Solid Tumor Clinical Trials
Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced that it has received approval from the National Medical...
Kelun Pharma’s SKB264 ADC Receives Breakthrough Therapy Designation for TNBC
The Center for Drug Evaluation (CDE) website indicates that Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE:...
Burning Rock Biotech Launches PREVENT Study for Early Cancer Detection
Chengdu-based medical device firm Burning Rock Biotech Ltd (NASDAQ: BNR) announced the launch of a...
Harbour BioMed’s Partner NK Celltech Raises RMB 100M in Series A Financing
China-based Harbour BioMed (HKG: 2142) announced that its strategic partner NK Celltech, a company focusing...
NMPA Releases 55th Batch of Reference Drugs for Generic Evaluation
The National Medical Products Administration (NMPA) has released the 55th batch of reference drugs for...
BeiGene’s Tislelizumab Shows Survival Benefit in Esophageal Cancer Study
BeiGene (NASDAQ: BGNE) has released the latest results of the global Phase III RATIONALE 306...
NMPA Releases Work Plans for Temporary Import of Urgently Needed Drugs
The National Medical Products Administration (NMPA) has officially released the “Work Plan for the Temporary...